Sugi Predict

Sugi Predict / Compounds / SCHEMBL935876

SCHEMBL935876

SCHEMBL935876

COc1cc(N)c(Br)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.67
▸ L3MBTL1 Q9Y468 1/20 0.67
▸ MAPT P10636 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ PRKDC P78527 1/20 0.48
▸ LCK P06239 1/20 0.47
▸ FYN P06241 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ HTR2A P28223 4/20 0.44
▸ TAAR1 Q96RJ0 3/20 0.44
▸ HTR2C P28335 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ PTGS1 P23219 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23759796 0.88 L3MBTL1 (0.78) POLBL3MBTL1MAPTNPSR1NPC1
SCHEMBL23885270 0.88 POLB (0.58) POLBL3MBTL1MAPTNPSR1NPC1
SCHEMBL30052469 0.88 POLB (0.58) POLBL3MBTL1MAPTNPSR1NPC1
SCHEMBL30038728 0.84 POLB (0.50) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL27685954 0.84 L3MBTL1 (0.50) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL3342651 0.84 POLB (0.50) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL19411031 0.84 POLB (0.50) POLBL3MBTL1MAPTNPSR1PRKDC
SCHEMBL3343872 0.84 POLB (0.54) POLBL3MBTL1MAPTNPSR1NPC1
SCHEMBL5866562 0.84 POLB (0.59) POLBL3MBTL1MAPTNPSR1PRKDC
Hydrazinecarboxamide SCHEMBL1464190 0.83 KDM4E (0.50) POLBL3MBTL1MAPTNPSR1PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288552-B2 Dihydropyridone amidesas P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-10-16 — — US claimed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
EP-4125914-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2023-02-08 — — EP disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 — — CN disclosed
WO-2021202977-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-10-07 — — WO disclosed
CN-106946857-A 3-triazole compounds of Tarceva 1,2,3 with antitumor activity and its preparation method and application 河南师范大学 2017-07-14 — — CN disclosed
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2016-05-12 — — US disclosed
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2016-05-12 — — US disclosed
EP-2456440-B1 QUINOLINONE PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 — — EP disclosed
EP-2456440-B1 QUINOLINONE PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 — — EP disclosed
WO-2010072605-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 — — WO disclosed
WO-2010072605-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 — — WO disclosed
WO-2010072599-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 — — WO disclosed
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 — — US disclosed
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 — — US disclosed
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 — — US disclosed
US-20100160389-A1 DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 — — US disclosed
US-20100160389-A1 DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 — — US disclosed
US-20100160389-A1 DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 — — US disclosed
US-20080214576-A1 Topoisomerase Inhibitors and Prodrugs THRESHOLD PHARMACEUTICALS, INC. (US) 2008-09-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP POLB 192/4885L3MBTL1 4734/4885MAPT 1478/4885
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS P2RY1, P2RX1, P2RX3 POLB 4130/4885L3MBTL1 4395/4885MAPT 1035/4885
US-20100160389-A1 DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS P2RX3, P2RX1, P2RY1 POLB 4459/4885L3MBTL1 4605/4885MAPT 2793/4885
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST KRT18, CYB5R3, CBR3 POLB 123/4885L3MBTL1 4036/4885MAPT 863/4885
US-20080214576-A1 Topoisomerase Inhibitors and Prodrugs TOP2A, TOP1, TOP2B POLB 17/4885L3MBTL1 1178/4885MAPT 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.